Boston Scientific (NYSE:BSX) Price Target Cut to $68.00 by Analysts at Bank of America

Boston Scientific (NYSE:BSX) had its price objective decreased by stock analysts at Bank of America from $105.00 to $68.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the medical equipment provider’s stock. Bank of America‘s target price would suggest a potential upside of 22.88% from the stock’s current price.

Several other equities research analysts also recently commented on BSX. Barclays lowered their price objective on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating for the company in a research note on Thursday, April 23rd. Weiss Ratings downgraded Boston Scientific from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday. Wall Street Zen downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. Sanford C. Bernstein reissued an “outperform” rating and issued a $112.00 target price on shares of Boston Scientific in a research report on Friday, February 6th. Finally, Jefferies Financial Group cut their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, April 22nd. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $92.83.

Boston Scientific Stock Up 5.0%

NYSE:BSX traded up $2.66 during midday trading on Monday, reaching $55.34. 7,206,940 shares of the stock traded hands, compared to its average volume of 16,500,674. Boston Scientific has a 12-month low of $52.52 and a 12-month high of $109.50. The business has a 50-day moving average of $63.40 and a two-hundred day moving average of $81.65. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.22 and a current ratio of 1.90. The stock has a market capitalization of $82.24 billion, a PE ratio of 23.15, a price-to-earnings-growth ratio of 0.97 and a beta of 0.62.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the firm posted $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts forecast that Boston Scientific will post 3.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Murphy & Mullick Capital Management Corp raised its holdings in shares of Boston Scientific by 200.0% during the third quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares during the last quarter. FWL Investment Management LLC acquired a new stake in shares of Boston Scientific during the 2nd quarter worth approximately $26,000. Swiss RE Ltd. acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Garton & Associates Financial Advisors LLC acquired a new stake in shares of Boston Scientific during the 4th quarter worth approximately $26,000. Finally, United Community Bank grew its stake in shares of Boston Scientific by 115.7% during the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific announced a $1.5 billion strategic investment in MiRus LLC, giving it about a 34% stake and an exclusive option to acquire MiRus’ structural heart/TAVR business after clinical and regulatory milestones. Investors may view this as a meaningful long-term growth catalyst in the fast-growing transcatheter aortic valve market.
• Positive Sentiment: The company also launched a $2 billion accelerated share repurchase as part of its existing buyback authorization. That kind of buyback can support earnings per share and signals management confidence in Boston Scientific’s outlook.
• Positive Sentiment: BTIG reaffirmed its Buy rating on BSX and maintained a $80 price target, reinforcing the view that analysts still see upside from current levels.
• Neutral Sentiment: There was also broader pressure on healthcare stocks in premarket trading, which may have offset some of the company-specific enthusiasm.
• Negative Sentiment: Recent insider trading data shows multiple executive sales over the past six months, which is not a major near-term driver but can temper sentiment for some investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.